Dec 06, 2022 / 09:30PM GMT
Operator
Welcome to the Rani Therapeutics RT-102 Phase 1 Part 2 Repeat-Dose Setting conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. (Operator Instructions) As a reminder, this call is being recorded today, Tuesday, December 6, 2022.
I would now like to turn the conference call over to Lawrence Watts, Managing Director at Gilmartin Group. Please go ahead.
Lawrence Watts - Gilmartin Group - Moderator
Thank you, operator. Joining us on the call today from Rani Therapeutics are Chief Executive Officer, Talat Imran; Chief Financial Officer, Svai Sanford; Chief Scientific Officer, Dr. Mir Hashim; and Vice President of Clinical Development, Dr. Arvinder Dhalla. please turn to slide 2.
During this conference call, management will make forward-looking statements that are subject to risks and uncertainties related to the future events and/or financial performance of the company. These forward-looking statements are subject to a number of risks, uncertainties, and
Rani Therapeutics Holdings Inc To Discuss The Topline Results From The Phase 1 Part 2 Repeat Dose Study of RT-102 Call Transcript
Dec 07, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers